Who We Are & What We Do
Granules is a world class, large scale manufacturing company partnering with
market leaders to offer pharmaceutical products and services. We have a long
history as a producer of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and
finished dosages (FDs). We
support customers with our unique value, extensive product range and global
network of associates.
We are a fully vertically integrated pharmaceutical manufacturing company with
three core lines:
Our integrated model allows us to provide products throughout the value chain in
a cost-effective and efficient manner. We serve over 300 customers in 50
countries through our sales offices in India, U.S., U.K., Colombia and China.
Active Pharmaceutical Ingredients (APIs) – Granules has 3 factories
manufacturing APIs. We are among the top global manufacturers of Paracetamol and
Pharmaceutical Formulation Intermediates (PFIs) – Granules pioneered the concept
of PFIs and currently has 2 factories manufacturing single and multiple - active
PFIs. Our Gagillapur facility has an industry-leading 6 MT single batch size.
Finished Dosages (FDs) – Granules has a dedicated FD plant at the
Gagillapur facility. Our plant has the capacity to produce 6 billion tablets
annually and is scalable up to 12 billion tablets. The facility has received
approval from U.S.FDA, Infarmed and the Australian TGA.
Our Value Proposition
Granules has highly sophisticated production processes in order to manufacture
a broad assortment of products, thereby supplying a wide range of products and
services to our customers in a flexible and reliable manner. Our products can be
used in a range of pharmaceutical applications and we are constantly developing
new products and variants to meet our customers' specific requirements.
We demonstrate our commitment to the pharmaceutical industry through a
high level of customer service. Our product specialists, supported by
application technologists, research scientists and regulatory advisers are able
to provide immediate advice and customer support. By offering unique products
and a high level of customer support, we can offer our customers the competitive
advantage that is vital in the highly competitive pharmaceutical sector.
Granules encourage its customers to replace their conventional strategy of
captive manufacturing with prudent outsourcing. Our value proposition comprises of
The manufacture of PFIs (strategically backward integrated through the in-house
manufacture of APIs) to finished dosages (tablets in bulk).
Putting customers at ease by filing ANDA / dossiers for finished dosages, which
are repacked and marketed by the customers under their own brand name.
Relief for customers from regulatory rigors as well as manufacturing and
cleaning process validation responsibilities.
Significant savings in sampling, analytical, regulatory, R&D and manufacturing